Phathom Pharmaceuticals PHAT
$4.66 −$0.42 (-8.27%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.66 0.00%
Open$4.93
Prev close$5.08
Day range$4.62 – $5.15
Volume1.33M
Market cap$378.82M
P/E (TTM)–
Dividend yield–
PHAT Stock News
Headlines matching Phathom Pharmaceuticals or the PHAT ticker, most recent first.
- Leerink Partners Initiates Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Announces Target Price $10
- H.C. Wainwright Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)
- H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
- Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $14 Negative
- Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 Negative
- Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20
- Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 Negative
- Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $22 Negative
- Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.00 per Share, Vs. FactSet Est of $-0.19
- Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28
- Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25
- Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating
- Barclays Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $18
- A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28
- Barclays Upgrades Phathom Pharmaceuticals(PHAT.US) to Buy Rating, Raises Target Price to $18 Positive
No comments yet — be the first to weigh in on PHAT.
Sign in to join the discussion.